How to access Kerendia from the UAE — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A UAE patient with chronic kidney disease associated with type 2 diabetes (CKD in T2D) may receive a prescription for Kerendia (finerenone) from their treating nephrologist or cardio-renal specialist. Kerendia is FDA-approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalisation for heart failure in CKD associated with T2D. It is developed by Bayer. In the UAE, Kerendia availability through local supply is uneven across institutions; access is commonly coordinated through the named-patient pathway where a specific facility does not reliably stock it.

This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Kerendia is an oral non-steroidal selective mineralocorticoid receptor antagonist (MRA) taken once daily at 10 mg or 20 mg. Compared with steroidal MRAs (spironolactone, eplerenone), finerenone has a distinct selectivity profile and a hyperkalaemia-risk profile that requires structured potassium monitoring. Eligibility is anchored in documented CKD (typically uACR elevation and eGFR within labelled range) plus T2D. Your nephrologist establishes baseline potassium, eGFR, uACR, and sets the potassium-monitoring cadence.

Is Kerendia legally importable into the UAE?

Yes — through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework, with parallel authority through the Department of Health (DoH) in Abu Dhabi and the Dubai Health Authority (DHA) in Dubai depending on where the prescribing facility sits.

The mechanism permits a UAE-licensed physician to import a medicine not routinely available at the institution when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent alternative is suitable and available at that institution, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented.

How the pathway works, step by step

1. Consultation with your treating nephrologist or cardio-renal specialist. CKD documentation, T2D confirmation, potassium trajectory, and clinical rationale.
2. Baseline assessment. eGFR, uACR, serum potassium, HbA1c, and potassium-monitoring plan.
3. MoHAP named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, strength, and monitoring plan.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Kerendia from authorised distribution under DSCSA.
5. Ambient shipment. Kerendia ships under controlled ambient conditions with chain-of-custody documentation.
6. Arrival and dispensing. The hospital pharmacy releases the bottle to the patient with potassium-monitoring instructions.

What documentation your physician needs

• Clinical rationale letter confirming CKD-in-T2D indication and Kerendia as the indicated therapy
• Verification of UAE medical license
• Baseline eGFR, uACR, serum potassium, HbA1c
• Potassium-monitoring cadence plan consistent with FDA labeling
• Planned dosing strength (10 mg or 20 mg) and titration plan

Reserve Meds provides a physician documentation kit bundling templates MoHAP reviewers expect for nephrology named-patient imports, including the potassium-monitoring plan central to Kerendia adherence.

Costs and timing

Kerendia's US cash-pay reference cost sits in an indicative 2026 annual range of roughly USD 7,500–9,000 for continuous daily dosing. International logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. These figures are indicative, not guaranteed.

Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 14–28 days from the moment a complete MoHAP application is submitted.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

Reserve Meds's role

• Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and MoHAP review.
• Logistics. Ambient-controlled shipment to your prescribing hospital.
• Concierge case lead. A named point of contact coordinating monthly refills and monitoring reminders.

What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating nephrologist. We operate on a waitlist basis during pre-launch.

Frequently asked

Is this legal in the UAE? Yes, when executed through the MoHAP / DoH / DHA named-patient framework with appropriate documentation. See our trust and compliance page.

How does Kerendia compare with spironolactone? Both are mineralocorticoid receptor antagonists, but Kerendia is non-steroidal and selective with a distinct hyperkalaemia and outcomes profile in CKD-T2D populations, supported by FIDELIO-DKD and FIGARO-DKD outcomes trials.

What monitoring is essential? Serum potassium before initiation, at 4 weeks, then periodically — your nephrologist sets the full cadence consistent with FDA labeling, including holding or titrating based on potassium.

Will insurance cover this? Cash-pay is the default for named-patient imports. Some UAE private insurers consider case by case; we supply documentation but do not process claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Kerendia coordination.

> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.